Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Nov;68(5):1261–1271. doi: 10.1172/JCI110372

Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.

D M Slovik, R M Neer, J T Potts Jr
PMCID: PMC370921  PMID: 7298851

Abstract

Since studies in animals and humans have shown that parathyroid hormone can stimulate bone formation and increase trabecular bone, and patients with primary and secondary hyperparathyroidism may exhibit osteosclerosis, we evaluated the effect of short-term administration of human parathyroid hormone, hPTH-(1--34), in patients with osteoporosis. Six patients with osteoporosis underwent detailed studies including blood and urinary measurements of calcium, phosphate, and magnesium; 47Ca kinetic studies; and 18-d balance studies before and during the short-term administration (3--4 wk) of a daily subcutaneous injection of hPTH fragment 1--34 given as 450 or 750 U/dose. The mean fasting plasma calcium values rose slightly after hPTH-(1--34) administration, primarily in the high-dose group. There was no difference in the mean fasting plasma inorganic phosphate levels. The mean daily urinary excretion of calcium and phosphate was significantly increased in patients given the higher dose. In patients given 750 U, net intestinal calcium absorption increased, phosphate absorption increased, calcium balance improved, and phosphate balance improved. In patients given 450 U, calcium balance and phosphate balance worsened. 47Ca kinetic studies showed a minimal increase in bone accretion rate, a decrease in the mean transit time of calcium in the exchangeable pools, and a decrease in the exchangeable-pool size. In all six patients there was an increased renal clearance of 47Ca as a result of hPTH-(1--34) administration. These studies indicate that low doses of parathyroid hormone may promote bone formation, whereas higher doses clearly have an adverse effect on the skeleton.

Full text

PDF
1261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albright F., Bauer W., Claflin D., Cockrill J. R. STUDIES IN PARATHYROID PHYSIOLOGY: III. The Effect of Phosphate Ingestion in Clinical Hyperparathyroidism. J Clin Invest. 1932 Mar;11(2):411–435. doi: 10.1172/JCI100423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Belsey R. E., DeLuca H. F., Potts J. T., Jr A rapid assay for 25-OH-vitamin D3 without preparative chromatography. J Clin Endocrinol Metab. 1974 Jun;38(6):1046–1051. doi: 10.1210/jcem-38-6-1046. [DOI] [PubMed] [Google Scholar]
  3. Bilezikian J. P., Canfield R. E., Jacobs T. P., Polay J. S., D'Adamo A. P., Eisman J. A., DeLuca H. F. Response of 1alpha,25-dihydroxyvitamin D3 to hypocalcemia in human subjects. N Engl J Med. 1978 Aug 31;299(9):437–441. doi: 10.1056/NEJM197808312990902. [DOI] [PubMed] [Google Scholar]
  4. Birge S. J., Peck W. A., Berman M., Whedon G. D. Study of calcium absorption in man: a kinetic analysis and physiologic model. J Clin Invest. 1969 Sep;48(9):1705–1713. doi: 10.1172/JCI106136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brewer H. B., Jr, Fairwell T., Ronan R., Sizemore G. W., Arnaud C. D. Human parathyroid hormone: amino-acid sequence of the amino-terminal residues 1-34. Proc Natl Acad Sci U S A. 1972 Dec;69(12):3585–3588. doi: 10.1073/pnas.69.12.3585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Connor T. B., Freijanes J., Stoner R. E., Martin L. G., Jowsey J. Generalized osteosclerosis in primary hyperparathyroidism. Trans Am Clin Climatol Assoc. 1974;85:185–201. [PMC free article] [PubMed] [Google Scholar]
  7. Doyle F. H. Radiological patterns of bone disease associated with renal glomerular failure in adults. Br Med Bull. 1972 Sep;28(3):220–224. doi: 10.1093/oxfordjournals.bmb.a070932. [DOI] [PubMed] [Google Scholar]
  8. Fraser D. R., Kodicek E. Regulation of 25-hydroxycholecalciferol-1-hydroxylase activity in kidney by parathyroid hormone. Nat New Biol. 1973 Feb 7;241(110):163–166. doi: 10.1038/newbio241163a0. [DOI] [PubMed] [Google Scholar]
  9. Gallagher J. C., Wilkinson R. The effect of ethinyloestradiol on calcium and phosphorus metabolism of post-menopausal women with primary hyperparathyroidism. Clin Sci Mol Med. 1973 Dec;45(6):785–802. doi: 10.1042/cs0450785. [DOI] [PubMed] [Google Scholar]
  10. Garabedian M., Holick M. F., Deluca H. F., Boyle I. T. Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc Natl Acad Sci U S A. 1972 Jul;69(7):1673–1676. doi: 10.1073/pnas.69.7.1673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Genant H. K., Baron J. M., Straus F. H., Paloyan E., Jowsey J. Osteosclerosis in primary hyperparathyroidism. Am J Med. 1975 Jul;59(1):104–113. doi: 10.1016/0002-9343(75)90327-7. [DOI] [PubMed] [Google Scholar]
  12. Hesp R., Williams D., Rinsler M., Reeve J. A comparison of chromium sesquioxide and [51Cr]chromic chloride as inert markers in calcium balance studies. Clin Sci (Lond) 1979 Jul;57(1):89–92. doi: 10.1042/cs0570089. [DOI] [PubMed] [Google Scholar]
  13. KAYE M., PRITCHARD J. E., HALPENNY G. W., LIGHT W. Bone disease in chronic renal failure with particular reference to osteosclerosis. Medicine (Baltimore) 1960 May;39:157–190. [PubMed] [Google Scholar]
  14. Kalu D. N., Doyle F. H., Pennock J., Foster G. V. Parathyroid hormone and experimental osteosclerosis. Lancet. 1970 Jun 27;1(7661):1363–1366. doi: 10.1016/s0140-6736(70)91271-7. [DOI] [PubMed] [Google Scholar]
  15. Keutmann H. T., Sauer M. M., Hendy G. N., O'Riordan L. H., Potts J. T., Jr Complete amino acid sequence of human parathyroid hormone. Biochemistry. 1978 Dec 26;17(26):5723–5729. doi: 10.1021/bi00619a019. [DOI] [PubMed] [Google Scholar]
  16. Kivirikko K. I., Laitinen O., Prockop D. J. Modifications of a specific assay for hydroxyproline in urine. Anal Biochem. 1967 May;19(2):249–255. doi: 10.1016/0003-2697(67)90160-1. [DOI] [PubMed] [Google Scholar]
  17. LOEVINGER R., BERMAN M. Efficiency criteria in radioactivity counting. Nucleonics. 1951 Jul;9(1):26–39. [PubMed] [Google Scholar]
  18. Melick R. A., Gill J. R., Jr, Berson S. A., Yalow R. S., Bartter F. C., Potts J. T., Jr, Aurbach G. D. Antibodies and clinical resistance to parathyroid hormone. N Engl J Med. 1967 Jan 19;276(3):144–147. doi: 10.1056/NEJM196701192760304. [DOI] [PubMed] [Google Scholar]
  19. Neer R., Berman M., Fisher L., Rosenberg L. E. Multicompartmental analysis of calcium kinetics in normal adult males. J Clin Invest. 1967 Aug;46(8):1364–1379. doi: 10.1172/JCI105629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Niall H. D., Sauer R. T., Jacobs J. W., Keutmann H. T., Segre G. V., O'Riordan J. L., Aurbach G. D., Potts J. T., Jr The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci U S A. 1974 Feb;71(2):384–388. doi: 10.1073/pnas.71.2.384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Parfitt A. M. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism. 1976 Aug;25(8):909–955. doi: 10.1016/0026-0495(76)90124-4. [DOI] [PubMed] [Google Scholar]
  22. Parsons J. A., Reit B., Robinson C. J. A chick bioassay for parathyroid hormone. Endocrinology. 1973 Feb;92(2):454–462. doi: 10.1210/endo-92-2-454. [DOI] [PubMed] [Google Scholar]
  23. Pugsley L. I., Selye H. The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat. J Physiol. 1933 Jul 28;79(1):113–117. doi: 10.1113/jphysiol.1933.sp003032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rasmussen H., Wong M., Bikle D., Goodman D. B. Hormonal control of the renal conversion of 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol. J Clin Invest. 1972 Sep;51(9):2502–2504. doi: 10.1172/JCI107065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Reeve J., Hesp R., Williams D., Hulme P., Klenerman L., Zanelli J. M., Darby A. J., Tregear G. W., Parsons J. A. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet. 1976 May 15;1(7968):1035–1038. doi: 10.1016/s0140-6736(76)92216-9. [DOI] [PubMed] [Google Scholar]
  26. Reeve J., Meunier P. J., Parsons J. A., Bernat M., Bijvoet O. L., Courpron P., Edouard C., Klenerman L., Neer R. M., Renier J. C. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980 Jun 7;280(6228):1340–1344. doi: 10.1136/bmj.280.6228.1340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Reeve J. The turnover time of calcium in the exchangeable pools of bone in man and the long-term effect of a parathyroid hormone fragment. Clin Endocrinol (Oxf) 1978 Jun;8(6):445–455. doi: 10.1111/j.1365-2265.1978.tb02181.x. [DOI] [PubMed] [Google Scholar]
  28. Reeve J., Tregear G. W., Parsons J. A. Priliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis. Calcif Tissue Res. 1976 Aug;21 (Suppl):469–477. [PubMed] [Google Scholar]
  29. Reeve J., Wootton R., Hesp B. A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as a tracer for bone calcium. Calcif Tissue Res. 1976 Apr 20;(2):121–135. doi: 10.1007/BF02546402. [DOI] [PubMed] [Google Scholar]
  30. Rowe J. W., Andres R., Tobin J. D. Letter: Age-adjusted standards for creatinine clearance. Ann Intern Med. 1976 May;84(5):567–569. doi: 10.7326/0003-4819-84-5-567. [DOI] [PubMed] [Google Scholar]
  31. Segre G. V., Tregear G. W., Potts J. T., Jr Development and application of sequence-specific radioimmunoassays for analysis of the metabolism of parathyroid hormone. Methods Enzymol. 1975;37:38–66. doi: 10.1016/s0076-6879(75)37005-5. [DOI] [PubMed] [Google Scholar]
  32. Singh M., Nagrath A. R., Maini P. S. Changes in trabecular pattern of the upper end of the femur as an index of osteoporosis. J Bone Joint Surg Am. 1970 Apr;52(3):457–467. [PubMed] [Google Scholar]
  33. Teitelbaum S. L., Rosenberg E. M., Richardson C. A., Avioli L. V. Histological studies of bone from normocalcemic post-menopausal osteoporotic patients with increased circulating parathyroid hormone. J Clin Endocrinol Metab. 1976 Mar;42(3):537–543. doi: 10.1210/jcem-42-3-537. [DOI] [PubMed] [Google Scholar]
  34. Tregear G. W., van Rietschoten J., Greene E., Niall H. D., Keutmann H. T., Parsons J. A., O'Riordan J. L., Potts J. T., Jr Solid-phase synthesis of the biologically active N-terminal 1 - 34 peptide of human parathyroid hormone. Hoppe Seylers Z Physiol Chem. 1974 Apr;355(4):415–421. doi: 10.1515/bchm2.1974.355.1.415. [DOI] [PubMed] [Google Scholar]
  35. Walker D. G. The induction of osteopetrotic changes in hypophysectomized, thyroparathyroidectomized and intact rats of various ages. Endocrinology. 1971 Dec;89(6):1389–1406. doi: 10.1210/endo-89-6-1389. [DOI] [PubMed] [Google Scholar]
  36. Walton R. J., Bijvoet O. L. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975 Aug 16;2(7929):309–310. doi: 10.1016/s0140-6736(75)92736-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES